Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud [2]. - The complaint claims that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) Seeking Recovery for Investors – Contact Levi & Korsinsky